reSept ASD Occluder
Phase 3- Indications
- Atrial septal defect
Company intelligence / Profile preview
atHeart Medical
Baar, Zug, Switzerlandatheartmedical.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
The company’s reSept ASD Occluder has demonstrated long-term clinically effective closure of ASDs in initial clinical experience. It aims to reduce complications associated with permanent metal implants and preserve future treatment options. The ASCENT-ASD pivotal trial will enroll up to 250 patients globally to evaluate safety and efficacy compared to established performance goals for FDA-approved devices.
- Therapeutic areas
- Cardiovascular
- Modalities
- Device (specifically transcatheter septal occluder)Bioresorbable implant/device
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on atHeart Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atHeart Medical.